LifeStance Q4 revenue $190.1M (+61% YoY); net loss $108M; 2022 guidance reaffirmed

LifeStance Health Group, Inc.

Full-year 2021 revenue $667.5M (+77% YoY); net loss $307.2M largely from stock-based compensation.
Q4 Adjusted EBITDA $11.4M (6.0% of revenue), down 31% YoY; full-year Adjusted EBITDA $49.2M (7.4% of revenue).
Clinician base grew 55% to 4,790; 415 net adds in Q4 and 1,693 for the full year.
2022 guidance: revenue $865-885M, Center Margin $240-255M, Adjusted EBITDA $63-67M.
Q1 2022 revenue expected $195-200M; Omicron impact estimated at $3-7M; de novo openings moderated to 80-90.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.